Thank you for your interest in Glycostem. For members of the press and other interested parties, links on this page are downloadable news releases and images. Collectively, these media kit materials will provide a comprehensive overview of our company, our technology and our achievements in Natural Killer (NK) cells research and development.
If you have any questions, please feel free to contact Glycostem's CEO directly. Troels Jordansen may be reached via email, Troels@Glycostem.com, or by calling his mobile at +31 6 1834 5326.
In the press
- Biopharma Dealmakers - Nature: Natural killer cells making better cancer immunotherapies
- Biopharma Dealmakers - Nature: Glycostem launches pivotal oncology trial with evolved naked natural killer cells
- Off-the-shelf NK cells in hematologic malignancies and oncology
- Umbilical cord blood NK cells offer multiple advantages for cancer immunotherapy: lessons learned from Glycostem’s orphan drug oNKord®
Promotional pictures (high and low resolution)
These pictures are meant for media publications only. Please see our copyright information in this website's footer.